Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers
Ayat Lashen(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Mashael Algethami(University of Nottingham), Shatha Alqahtani(University of Nottingham), Mohammad R. Akbari(University of Toronto), Sudha Sharma(Shobhit University), Ahmed Shoqafi(University of Nottingham), Jennie N. Jeyapalan(University of Nottingham), Nigel P. Mongan(University of Nottingham), Abdulbaqi Al-Kawaz(University of Nottingham), Andrew R. Green(Nottingham Biomedical Research Centre), Michael S. Toss(Nottingham City Hospital)
Cited by 5
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Germline <i>BRCA</i> Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
|Journal of Clinical Oncology|2015|396